Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

BACKGROUND: Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Buti, Maria, Fung, Scott, Gane, Edward, Afdhal, Nezam H., Flisiak, Robert, Gurel, Selim, Flaherty, John F., Martins, Eduardo B., Yee, Leland J., Dinh, Phillip, Bornstein, Jeffrey D., Mani Subramanian, G., Janssen, Harry L. A., George, Jacob, Marcellin, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387268/
https://www.ncbi.nlm.nih.gov/pubmed/25788199
http://dx.doi.org/10.1007/s12072-015-9614-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387268/
https://www.ncbi.nlm.nih.gov/pubmed/25788199
http://dx.doi.org/10.1007/s12072-015-9614-4

Ejemplares similares